- Trials with a EudraCT protocol (19)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
19 result(s) found for: Glomeruli.
Displaying page 1 of 1.
EudraCT Number: 2015-003884-12 | Sponsor Protocol Number: EXTRAStudy | Start Date*: 2015-12-22 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA PAPA GIOVANNI XXIII | |||||||||||||
Full Title: A pilot, prospective, randomized, open-label, blinded endpoint (PROBE) histopathology trial to assess the effects of ACE- inhibition therapy on glomerular proliferative lesions in patients with ext... | |||||||||||||
Medical condition: Extracapillary glomerulonephritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000484-23 | Sponsor Protocol Number: NEFRTX1 | Start Date*: 2020-07-09 |
Sponsor Name:Vall d'Hebron Institute of Research | ||
Full Title: CHARACTERIZATION OF RITUXIMAB PHARMACOKINETICS IN PATIENTS WITH KIDNEY DISEASES WITH PRIMARY GLOMERULAR AFFECTATION | ||
Medical condition: KIDNEY DISEASES WITH PRIMARY GLOMERULAR AFFECTATION (glomerulonefritis membranosa, glomerulonefritis por cambios mínimos, vasculitis, glomerulosclerosis focal y segmentaria.) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: View results |
EudraCT Number: 2020-005835-60 | Sponsor Protocol Number: APHP200038 | Start Date*: 2021-08-11 |
Sponsor Name:Assistance Publique – Hôpitaux de Paris (AP-HP) | ||
Full Title: Induction therapy for lupus nephritis with no added oral corticosteroids : An open label randomised multicentre controlled trial comparing oral corticosteroids plus mycophenolate mofetil (MMF) ve... | ||
Medical condition: The study population will consist of Children (14 years and above) and adults (until 75 years old) with lupus nephritis ISN/RPS class III or IV (A or A/C) ± V with active lesions in at least 10% of... | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2017-001821-42 | Sponsor Protocol Number: CL011_168 | Start Date*: 2018-08-02 | |||||||||||
Sponsor Name:ChemoCentryx, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan (CCX168) in Patients with C3 Glomerulopathy | |||||||||||||
Medical condition: C3 glomerulopathy (C3G) is characterized by evidence of alternative complement activation based on C3 deposition in the glomeruli. There are two forms of the disease: dense deposit disease (DDD, fo... | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) DE (Completed) NL (Completed) ES (Completed) DK (Completed) FR (Completed) IT (Completed) IE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-000443-99 | Sponsor Protocol Number: MIGAN | Start Date*: 2008-04-09 | |||||||||||
Sponsor Name:Universitätsklinikum Ulm | |||||||||||||
Full Title: Comparison of the sequential maintenance therapy with Mycophenolat and Prednisolon to standard therapy after completed induction therapy – a multicenter, randomised, phase III intervention study fo... | |||||||||||||
Medical condition: progressive IgA-Nephritis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-000726-11 | Sponsor Protocol Number: SHP616-302 | Start Date*: 2016-03-08 | |||||||||||
Sponsor Name:Shire Viropharma, Inc. | |||||||||||||
Full Title: A randomized double-blind placebo-controlled study to evaluate the efficacy and safety of Cinryze® (C1 esterase inhibitor [human]) for the treatment of acute antibody-mediated rejection in kidney t... | |||||||||||||
Medical condition: Acute Antibody Mediated Rejection (AMR) in kidney transplant patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000027-14 | Sponsor Protocol Number: T-19-11318v19 | Start Date*: 2018-08-20 | |||||||||||
Sponsor Name:Imperial College London | |||||||||||||
Full Title: A Phase 2, Pilot Study to Assess the Safety and Efficacy of Fostamatinib in the Treatment Chronic Active Antibody Mediated Rejection in Renal Transplantation | |||||||||||||
Medical condition: Chronic active antibody mediated rejection of renal transplants | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Temporarily Halted) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002882-20 | Sponsor Protocol Number: | Start Date*: 2019-04-17 | |||||||||||
Sponsor Name:Imperial College London | |||||||||||||
Full Title: A multicentre randomised controlled trial to assess the safety and efficacy of adding rituximab to standard of care in treating acute antibody-mediated rejection in kidney transplantation (Transpla... | |||||||||||||
Medical condition: Renal Transplant antibody-mediated rejection | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-003022-32 | Sponsor Protocol Number: CL012_140 | Start Date*: 2019-10-12 | |||||||||||
Sponsor Name:ChemoCentryx, Inc. | |||||||||||||
Full Title: An Open Label, Intra-Subject Dose Escalation Study of CCX140-B in Subjects with Primary Focal Segmental Glomerulosclerosis (FSGS) and Nephrotic Syndrome | |||||||||||||
Medical condition: Primary Focal Segmental Glomerulosclerosis (FSGS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000835-30 | Sponsor Protocol Number: MONET | Start Date*: 2021-10-12 | |||||||||||
Sponsor Name:IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI | |||||||||||||
Full Title: RESCUE THERAPY WITH THE HUMAN ANTI-CD38 ANTIBODY MOR202 (FELZARTAMAB) IN PATIENTS WITH MEMBRANOUS NEPHROPATHY WHO FAILED ANTI-CD20 TARGETED THERAPY: A PILOT, PROOF-OF-CONCEPT STUDY | |||||||||||||
Medical condition: Membranous Nephropathy who Failed Anti-CD20 Target Therapy. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005830-14 | Sponsor Protocol Number: CVAY736K12301 | Start Date*: 2022-07-04 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: A randomized, double-blind, parallel group, placebo-controlled, multicenter Phase 3 trial to evaluate the efficacy, safety and tolerability of ianalumab on top of standard-of-care therapy in patien... | |||||||||||||
Medical condition: Lupus nephritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) HU (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) CZ (Trial now transitioned) EE (Ongoing) LT (Trial now transitioned) RO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-001365-26 | Sponsor Protocol Number: AN-IGN3321 | Start Date*: 2014-08-21 | |||||||||||
Sponsor Name:Anthera Pharmaceuticals, Inc | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Evaluate the Efficacy and Safety of Blisibimod Administration in Subjects with IgA Nephropathy | |||||||||||||
Medical condition: IgA Nephropathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Prematurely Ended) DE (Completed) IT (Prematurely Ended) HU (Completed) ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-016003-26 | Sponsor Protocol Number: 1.0 | Start Date*: 2010-05-06 | ||||||||||||||||
Sponsor Name:UHB NHS Foundation Trust | ||||||||||||||||||
Full Title: RANDOMISED PILOT TRIAL OF MYFORTIC FOR THE TREATMENT OF PRIMARY PROTEINURIC GLOMERULONEPHRITIS. | ||||||||||||||||||
Medical condition: Primary Proteinuric Glomeruolnephritis Focal segmental glomeruloscerosis and IgA nephropathy | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-003021-15 | Sponsor Protocol Number: CL011_140 | Start Date*: 2018-05-18 | |||||||||||
Sponsor Name:ChemoCentryx, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects with Focal Segmental Glomerulosclerosis (FSGS) | |||||||||||||
Medical condition: Focal Segmental Glomerulosclerosis (FSGS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) GB (Completed) PL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002674-39 | Sponsor Protocol Number: ACH471-205 | Start Date*: 2018-07-31 | |||||||||||
Sponsor Name:Achillion Pharmaceuticals, Inc. | |||||||||||||
Full Title: An Open-Label Phase 2 Proof-of-Concept Study in Patients with C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Treated with ACH-0144471 | |||||||||||||
Medical condition: biopsy-confirmed C3 Glomerulopathy (C3G) or idiopathic Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) and eGFR >30 mL/min/1.73 m^2 | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) NL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-003233-38 | Sponsor Protocol Number: WA41937 | Start Date*: 2021-03-02 | |||||||||||
Sponsor Name:F.Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A PHASE III, RANDOMIZED, OPEN-LABEL ACTIVE COMPARATOR-CONTROLLED MULTICENTER STUDY TO EVALUATE EFFICACY AND SAFETY OF OBINUTUZUMAB IN PATIENTS WITH PRIMARY MEMBRANOUS NEPHROPATHY | |||||||||||||
Medical condition: Primary Membranous Nephropathy (pMN) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000971-18 | Sponsor Protocol Number: SynAct-CS003 | Start Date*: 2020-05-28 | ||||||||||||||||
Sponsor Name:SynAct Pharma ApS | ||||||||||||||||||
Full Title: An exploratory, randomized, double-blind, multicenter, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, and efficacy of AP1189 daily doses versus placebo administered ... | ||||||||||||||||||
Medical condition: Idiopathic membranous nephropathy and severe proteinuria | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Trial now transitioned) NO (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004605-41 | Sponsor Protocol Number: 021IGAN17001 | Start Date*: 2018-10-04 | |||||||||||
Sponsor Name:Retrophin, Inc. | |||||||||||||
Full Title: A Randomized, Multicenter, Double-blind, Parallel-group, Active-control Study of the Efficacy and Safety of Sparsentan for the Treatment of Immunoglobulin A Nephropathy | |||||||||||||
Medical condition: Immunoglobulin A Nephropathy (IgAN) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Trial now transitioned) LT (Trial now transitioned) BE (Trial now transitioned) FR (Trial now transitioned) CZ (Trial now transitioned) ES (Ongoing) EE (Ongoing) PT (Trial now transitioned) PL (Trial now transitioned) HR (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-005357-29 | Sponsor Protocol Number: WA20500 | Start Date*: 2008-05-07 |
Sponsor Name:F. Hoffmann-La Roche Ltd | ||
Full Title: A Randomised, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study To Evaluate The Efficacy and Safety of Two Doses of Ocrelizumab in Subjects With WHO or ISN Class III or IV Nephrit... | ||
Medical condition: Lupus Nephritis | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) FR (Completed) DE (Completed) HU (Completed) ES (Completed) NL (Completed) PT (Prematurely Ended) SE (Completed) PL (Prematurely Ended) BG (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
